Capvizr
THE DEAL, AT A GLANCE

Transcripta Bio

From the announcement
01
MoleculesDrug research
Medicine development
What it doesLed by CEO and Founder Chris Moxham, Transcripta Bio is an AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02Who is involvedBacked by CEO, Founder Chris Moxham, neuromuscular diseasesFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03What happenedTranscripta Bio raised $24M Series AFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
04Why it mattersTranscripta Bio’s Series A supports an AI-powered drug discovery platform focused on neurological and neuromuscular diseases.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Transcripta Bio · Financing Record

Explore source-linked visual explanations for Transcripta Bio. Unsupported claims are withheld while source review continues.

Record 8953 · Recorded date: Needs review

What it does

Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.

Open record 8953 →

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime